Total Revenue: $88.8 million, a 5.8% increase year-over-year. Direct to Consumer Sales: Decreased 23.2% to $19.2 million. Domestic Business to Business Revenue: Increased 35.1% to $23.4 million.

Inogen Inc (NASDAQ:INGN) achieved its 6th consecutive quarter of mid-single-digit growth, with approximately $92 million in revenue. The company reported a 19% increase in overall unit volumes, driven ...

Inogen's price performance has been poor this year, but a closer look at the numbers suggests that the market's negativity may be unwarranted. Management is actively taking steps to address the ...

Supply chain issues caused major problems for Inogen in FY22, and continued headwinds are expected in FY23. Management expects operational performance to improve in late FY23 but indicates that ...

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to ...

Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company ...

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the introduction of ...